Pubmed Biomarker Method Statistics Odds(95% CI) P-value Description
34420090 CTNNB1 6 (31.6%) p=0.017 In the multivariate analysis, only CTNNB1 exon 3 mutation appeared to be independently and significantly associated with tumour recurrence
34162378 isoform B of progesterone receptor OR 5.788 p=0.010 While marked reduction of PRB (≥ 30%) at 3-6 months' treatment correlated with faster remission
33754208 CHK1 HR=0.56 Higher expression of CHK1 in the cytoplasmic was associated with decreased risk of progression.
33754208 FBXW7 HR=0.80 higher nuclear FBXW7 was associated with decreased risk of progression
33754208 PPP2R1B HR=0.59 cytoplasmic PPP2R1B levels was associated with decreased risk of progression
33237570 P53 Univarite Cox regression analysis p<0.001 Univarite Cox regression analysis recommended that a P53 index with a threshold of 67% was significantly associated with recurrence
32920817 [ER + PR]/[P53 + Ki67] p=.004 multivariate analysis the combined ratio was independent risk factors of recurrence
32901849 CDK9 p<0.001 The CDK9 expression level in primary endometrial cancer tissues was significantly lower than that in metastatic and recurrent endometrial cancer tissues. These differences were statistically significant(recurrent vs. primary,)
30661222 STC2 p=0.013 High-expression of STC2 was significantly associated with disease recurrence
30661222 STC2 Multivariate analysis Multivariate analysis revealed that both the tumor grade and STC2 were independent predictors of disease recurrencence
30645608 GDF-15 1780 ng/L/ VS 1236 ng/L; 95% CI; 518-9475 ng/L VS 95% CI; 307-7030 ng/L p<0.001 Preoperative plasma level of GDF-15 was significantly higher for patients who experienced recurrence than for patients who did not develop recurrent disease
34420090 CTNNB1 p=0.012 In the univariate logistic regression model, tumours harbouring a CTNNB1 exon 3 mutation had a relative risk of relapse of 3.912
30645608 GDF-15 2818 ng/L/1857 ng/L, 95% CI 2088–3548 ng/L/95% CI; 1317–2398 ng/L p=0.001 Plasma levels of GDF-15 at recurrence were significantly higher than plasma levels of GDF-15 measured at time of primary diagnosis.
30645608 GDF-15 OR = 3.14; 95% CI 2.10–4.76 High plasma level GDF-15 predicts recurrent disease
30585737 miR-142 p<0.001 There was lower mRNA abundance of miR-142 in tumor samples in EC patients with recurrence than that in samples of EC patients without recurrence
30561762 MMR status p=.002 The recurrence rate for women who had dMMR was 28% compared with 10.5% for those who had iMMR
30561762 MMR status 14.1% vs 3% p=.003 The increase in distant recurrences among patients who had dMMR was even more pronounced
30521558 Patched-1 HR = 2.04, 95% CI 1.05–3.96 p=0.036 Patched-1 positivity conferred higher risk for relapse
30508211 CA125 multivariate analysis p=0.000 In multivariate analysis, both grade and conventional CA125 level were independent prognostic factors for the risk of recurrence
30508211 preoperative CA125 22.8% vs 8.9% p<0.0001 Recurrence developed in 22.8% and 8.9% of the patients with CA125 levels of ≥ 35 IU/mL and < 35 IU/mL, respectively
30508211 CA125 92.1 IU/mL vs. 34 IU/mL p<0.0001 In the whole group, the median CA125 level in patients who experienced a recurrence was higher than that in patients who did not experience recurrence (respectively, 92.1 IU/mL vs. 34 IU/mL;
29980240 L1CAM low level of L1CAM mRNA was expressed in recurrent compared to non-recurrent EC
34339705 TMEFF2 p<0.001 Positive TMEFF2 expressing cases were more liable to cancer progression and a higher incidence of relapse after therapy
29092787 Estradiol metabolites multivariate logistic regression analysis Hazard ratios (HRs) of 0.31 p=0.039 Preoperative levels of estriol (E3) were inversely associated with recurrence in a multivariate logistic regression analysis
29092787 Estradiol metabolites multivariate logistic regression analysis Hazard ratios (HRs) of 3.01 p=0.024 estrone-sulfate (E1-S) were inversely associated with recurrence in a multivariate logistic regression analysis
29092787 Estradiol metabolites HR=0.32 p=0.015 All circulating steroids declined considerably after surgery almost reaching those of healthy women, except 4-methoxy-E2 (4MeO-E2) for which postoperative levels increased by 35% and were associated to a 68% decreased risk of recurrence
28277313 androgen receptor (AR) p=0.009 AR expression was correlated with late disease recurrence
27488577 L1CAM HR 2.9; 95 % CI: 1.08-7.56 p=0.16 In patients who were not treated with chemotherapy, L1CAM was significantly associated with risk of relapse (HR 2.9; 95 % CI: 1.08-7.56; p = 0.04).
27121063 USP14 Median [Range]: 2.3 [1.7-3.0] vs. 2.0 [1.0-3.0] p=0.02 When comparing USP14 expression levels between patients who did and did not recur within 36 months, the median USP14 expression level was higher among the recurrent cases
27121063 USP14 odds ratio = 7.6 [95% confidence interval: 1.6-35.3] p=0.01 After adjustment, higher USP14 expression levels were highly associated with recurrence
26842712 NUCB2 log-rank test p=0.0004 NUCB2 status was significantly associated with increased risk of recurrence
26350184 TATI Mann-Whitney Z = -6.06653 p=0.00000 An increase in the concentration by more than 10.6% in the first 3 assays was significantly correlated with disease relapse
26350184 TATI Mann-Whitney Z = -4.97475 p=0.000001 An increase in the concentration by more than 10.6% in the first 3 assays was significantly correlated with local or distant recurrence
34339705 SOX17 p=0.001 SOX17 negative expression was positively correlated with recurrence
26166558 LSD1 p<0.001 LSD1 overexpression was significantly associated with recurrence
25505230 POLE proofreading mutations 6.2% vs 14.1% Women with POLE-mutant ECs had fewer recurrences
25355598 HABP1 p=0.009 High HABP1 expression was significantly associated with recurrence
25254562 CRHR1 p=0.023 CRHR1 status was significantly associated with an increased incidence of recurrence
25219463 ANXA2 p=0.01 From a total of 63 stage I tumors (31 associated with recurrences, and 32 not associated with recurrences; those tumors that end up in recurrent disease presented 18.29% higher ANXA2 levels in comparison to those that did not recur ( mean 210.37 vs. 177.85 histoscore)
25219463 ANXA2 mean 217.87 vs. 174.62 histoscore, p<0.0001 In samples of primary EEC from 93 patients including 43 primary carcinomas that did not relapse and 50 primary carcinomas that progressed to recurrent diseased (Supporting Information Table 4). ANXA2 expression was found to be a 24.76% superior in EEC that ended up in recurrent disease compared to those that did not recur (
25219463 ANXA2 mean 220.51 vs. 176.09 histoscore p=0.0002 When we evaluated stage I and stage II EEC together (78 cases; 38 associated with recurrence and 40 not associated with recurrence); tumors that recurred presented 25.22% higher ANXA2 levels in comparison with those that did not recur
25219463 ANXA2 Kaplan-Meier p=0.004 Kaplan-Meier relapse-free curve was lower for patients with ANXA2 histoscore in the interval 190 to 300 than for patients with ANXA2 histoscore in the interval 0 to 190,achieving statistical significance.
25219463 ANXA2 HR 5 2.99 p=0.004 The analysis of the relapse-free survival time clearly indicated that time to recurrence was much lower in patients with ANXA2 histoscore above 190
24972085 Yes-associated protein (YAP) p=0.046 Increased nuclear YAP expression was significantly associated with postoperative recurrence/metastasis
34339705 SOX17 p=0.001 SOX17 negative expression was positively correlated with recurrence of the tumor after successful therapy
24118160 (18)F-Fluorodeoxyglucose Among eight recurrent and one metastatic endometrial stromal sarcoma patients, four (44%) had positron emission tomography-positive findings
23781004 L1CAM Multivariable analyses hazard ratio [HR] = 16.33; 95% confidence interval [CI] = 10.55 to 25.28 Multivariable analyses revealed an increase in the likelihood of recurrence
23781004 L1CAM classification and regression decision tree (CRT) sensitivity = 0.74; specificity = 0.91 A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting recurrence
22824999 DNA ploidy p=0.03 A DNA ploidy parameter, 5c exceeding rate, was found to be a prognostic marker for recurrence
22644303 pHH3 univariate survival analysis p<0.0001 In univariate survival analysis, overexpression of pHH3 were associated with increased recurrence
22644303 survivin univariate survival analysis p<0.0001 In univariate survival analysis, overexpression of survivin were associated with increased recurrence
22617129 bFGF HR: 9.88, 95% CI: 2.63, 37.16 Cases with HGF-positive, bFGF-positive tumours had a higher risk of recurrence compared with cases with negative expression of both markers
15726651 PR OR 4.7; 95% CI: 1.3-17.1 Most interestingly, patients who carried the PROGINS variant and in whom a PR-expressing tumour was diagnosed were at significantly enhanced risk of relapse
15726651 PR OR 2.6; 95% CI: 0.9-7.6 The PROGINS polymorphism was observed in 16% of primary tumours from patients without, and in 34% of patients with, recurrence
15726651 PR p<0.05 The expression of PR was significantly lower in primary tumours from patients with recurrence (SI = 4.0 +/- 0.5) than in the tumours in the control group (SI = 5.6 +/- 0.5)
34162378 HOMA-IR OR 0.206 95% CI 0.056–0.755 p=0.017 While those with insulin resistance status (HOMA-IR ≥ 2.5) was negatively affected treatment time to remission
15661223 Smad7 p<0.004 For the 19 patients who recurred, median time to recurrence was 56.3 months for those with low Smad7 expression versus 30 months for those with high Smad7 expression
15498190 CK p<0.05 Among patients with stage I, II diseases, tumor recurrence rate was significantly higher in patients with positive CK or CA(125) expression in lymph nodes than in patients without CK or CA(125) expression
15498190 CK Multiple regression analysis Multiple regression analysis revealed that in stages I, II endometrial cancer, CK expression in lymph nodes in lymph nodes together with depth of myometrial invasion were relevant factors with tumor recurrence.
15498190 CA(125) Multiple regression analysis Multiple regression analysis revealed that in stages I, II endometrial cancer, CA(125) expression in lymph nodes together with depth of myometrial invasion were relevant factors with tumor recurrence.
15328195 E-cadherin multivariate Cox regression HR, 0.24; 95% CI, 0.062-0.97 p=0.045 On multivariate Cox regression, a higher E-cadherin expression score was associated with extrapelvic recurrence
15068320 DNA ploidy p<0.001 DNA ploidy revealed significantly less risk of relapse for diploid tumours than for aneuploid ones
14751145 fatty acid synthase (FAS) p=0.04 Statistical analysis revealed that FAS was the only two independent predictors of recurrence
12895227 p53 p=0.004 The difference in the invasive type (P < 0.001) and p53 expression between the recurrence and non-recurrence groups was significant in the univariate analysis.
12893199 MIB1 p=0.0303 There was a significant difference in MIB1 reactivity scores between patients who did or did not develop recurrence
12722380 Microvessel density index Microvessel count was related to likelihood of recurrence. We found statistically significant differences between patients who died after operation and patients with nonrecurrence process.
34162378 HOMA-IR OR 0.206 95% CI 0.056–0.755 p=0.017 Patient with a histological type of EC (compared with EAH) both negatively affected treatment time to remission
12130664 UPAR p=0.034 UPAR protein expression also positively correlated with rate of recurrence and mortality in patients with adenocarcinoma of the endometrium
11917578 AgNORs Values of PI ≥ 150 were associated with good local disease control (no recurrence at one year), and values of PI < 150 were associated with poor local disease control (recurrence at one year).
11917578 AgNORs A threshold value in the vicinity of 149 emerges, above which 100% of patients evidenced no recurrence and below which 100% of the patients evidenced recurrence at one year.
11516808 p53 univariate analysis p<0.001 In univariate analysis p53 overexpression had a positive correlation with a high risk of recurrence.
11516808 p53 multivariate analysis p<0.001 In multivariate analysis, p53 overexpression were independent prognostic indicators of recurrence.
11161861 VEGF Overexpressed cytosol VEGF (> 800 pg/mg) are independent risk factors for recurrence.
11161851 cytokeratin Multivariate analysis Multivariate analysis identified cytokeratin expression as an independent risk factor for recurrence in Stage I endometrial cancer.
10985893 CK-20 All 6 patients with recurrent disease were positive, and all subjects in the control group were negative
10452508 anti-repp 86 multivariate Cox regression analysis p=.002 A multivariate Cox regression analysis selected anti-repp 86 LI as significant prognosticators of recurrence;
8641618 MIB-1 p=0.002 Elevated MIB-1 staining was associated with an increased incidence of recurrence within 24 months of diagnosis
34162378 isoform B of progesterone receptor odds ratio [OR], 5.788 95% CI 1.531–21.889 p=0.010 Patients with a reduction in PRB (≥ 30%) at 3–6 months' treatment, significantly correlated with faster remission (odds ratio [OR], 5.788 95% CI 1.531–21.889 p=0.010)
8641618 MIB-1 p=0.003 Patients whose tumors had MIB-1 staining of greater than or equal to 39.0% had an increased chance of recurring over patients whose tumors stained less than 39.0%
8088608 CA19-9 in combination with CA125 The combined assay demonstrated a 71.9% positive rate at the time of detection of the recurrence (65.6% for CA125, 43.7% for CA19-9).
7909491 DNA ploidy univariable analysis With univariable analysis ploidy were predictive of the presence of persistent or recurrent disease.
34282107 TAM P=0.04 The counts of margin TAMs was significantly correlated with recurrence.
35429348 DJ-1 and HE4 P<0.05 It was found that the risk of early recurrence of uterine cancer increased (p<0,05) when the concentration of CA-125 exceeded the level of 29,3 U/ml, HE4 was above 79,3 pmol/l, DJ-1 was above 90,0 ng/ml and DKK-1 above 47,3 pg/ml 6 months after the end of primary treatment.
28259868 Small Foci p < 0.01 According to several factors, the presence of SC was only associated with recurrence ( p < 0.01). The sensitivity and specificity to predict recurrence were 100 and 93%, respectively.
34162378 HOMA-IR multivariate analysis OR= 0.206 p=0.017 Further multivariate analysis confirmed that baseline HOMA-IR ≥ 2.5 negatively affected treatment time to remission

Institutes for Systems Genetics, West China Hospital
     Copyright @ 2023 ISG. All Rights Reserved.